4.7 Article

Residual Kidney Function Decline and Mortality in Incident Hemodialysis. Patients

Journal

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 27, Issue 12, Pages 3758-3768

Publisher

AMER SOC NEPHROLOGY
DOI: 10.1681/ASN.2015101142

Keywords

-

Funding

  1. Abbott Laboratories (Alameda, CA)
  2. Abbvie
  3. Alexion
  4. Amgen, Inc. (Thousand Oaks, CA)
  5. American Society of Nephrology
  6. AstraZeneca Pharmaceuticals (Wilmington, DE)
  7. AVEO
  8. Chugai Pharmaceutical Co (Tokyo, Japan)
  9. DaVita, Inc.
  10. Fresenius
  11. Genetech
  12. Haymarket Media
  13. Hospira
  14. Kabi
  15. Keryx
  16. National Institutes of Health
  17. National Kidney Foundation
  18. Relypsa
  19. Resverlogix
  20. Sanofi US (Bridgewater, NJ)
  21. Shire
  22. Vifor
  23. ZS Pharma

Ask authors/readers for more resources

In patients with ESRD, residual kidney function (RKF) contributes to achievement of adequate solute clearance. However, few studies have examined RKF in patients on hemodialysis. In a longitudinal cohort of 6538 patients who started maintenance hemodialysis over a 4-year period (January 2007 through December 2010) and had available renal urea clearance (CLurea) data at baseline and 1 year after hemodialysis initiation, we examined the association of annual change in renal CLurea rate with subsequent survival. The median (interquartile range) baseline value and mean SD annual change of CLurea were 3.3 (1.9-5.0) and-1.1 +/- 2.8 ml/min per 1.73 m(2), respectively. Greater CLurea rate 1 year after hemodialysis initiation associated with better survival. Furthermore, we found a gradient association between loss of RKF and all-cause mortality: changes in CLurea rate of -6.0 and +3.0 ml/min per 1.73 m(2) per year associated with case mix-adjusted hazard ratios (95% confidence intervals) of 2.00 (1.55 to 2.59) and 0.61 (0.50 to 0.74), respectively (reference: -1.5 ml/min per 1.73 m(2) per year). These associations remained robust against adjustment for laboratory variables and ultra filtration rate and were consistent across strata of baseline CLurea, age, sex, race, diabetes status, presence of congestive heart failure, and hemoglobin, serum albumin, and serum phosphorus levels. Sensitivity analyses using urine volume as another index of RKF yielded consistent associations. In conclusion, RKF decline during the first year of dialysis has a graded association with all-cause mortality among incident hemodialysis patients. The clinical benefits of RKF preservation strategies on mortality should be determined.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available